Antiviral Drugs - Nordics

Nordics

In the Nordics, the revenue in the market of Antiviral Drugs market is estimated to reach US$0.53bn in 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2029) of 1.47%, leading to a market volume of US$0.57bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$30,640.00m in 2024.
The Nordics have seen a significant increase in the demand for antiviral drugs, driven by the region's high healthcare standards and proactive approach to public health.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Nordics has been on the rise in recent years.

Customer preferences: There is a growing demand for Antiviral Drugs in Nordics due to the increasing prevalence of viral infections. Customers are seeking effective treatments for viral infections such as influenza, HIV, and hepatitis. Additionally, the COVID-19 pandemic has further accelerated the demand for Antiviral Drugs.

Trends in the market: The Antiviral Drugs market in Nordics is witnessing a trend towards the development of new and innovative drugs. Pharmaceutical companies are investing heavily in research and development to create new drugs that are more effective and have fewer side effects. Additionally, there is a trend towards the development of combination therapies, which involve the use of two or more drugs to treat viral infections.

Local special circumstances: Nordics has a well-established healthcare system that provides universal access to healthcare services. This has led to a high level of awareness and demand for Antiviral Drugs in the region. Additionally, the region has a high prevalence of certain viral infections, such as hepatitis C, which has further increased the demand for Antiviral Drugs.

Underlying macroeconomic factors: Nordics has a strong and stable economy, which has enabled the region to invest heavily in healthcare and research and development. Additionally, the region has a high level of healthcare spending per capita, which has further supported the growth of the Antiviral Drugs market. The region also has a highly skilled workforce and a favorable regulatory environment, which has encouraged pharmaceutical companies to invest in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.